Download PDF
Hamostaseologie 2021; 41(06): 428-432
DOI: 10.1055/a-1661-0257
Review Article

Thromboinflammation as a Driver of Venous Thromboembolism

Nadine Gauchel
1   Department of Cardiology and Angiology I, University Heart Center Freiburg—Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Krystin Krauel
1   Department of Cardiology and Angiology I, University Heart Center Freiburg—Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Muataz Ali Hamad
1   Department of Cardiology and Angiology I, University Heart Center Freiburg—Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Christoph Bode
1   Department of Cardiology and Angiology I, University Heart Center Freiburg—Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Daniel Duerschmied
1   Department of Cardiology and Angiology I, University Heart Center Freiburg—Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
› Author Affiliations Funding Deutsche Forschungsgemeinschaft, #422681845
› Further Information
Also available at
   Permissions and Reprints

Abstract

Thrombus formation has been identified as an integral part in innate immunity, termed immunothrombosis. Activation of host defense systems is known to result in a procoagulant environment. In this system, cellular players as well as soluble mediators interact with each other and their dysregulation can lead to the pathological process of thromboinflammation. These mechanisms have been under intensified investigation during the COVID-19 pandemic. In this review, we focus on the underlying mechanisms leading to thromboinflammation as one trigger of venous thromboembolism.

Zusammenfassung

Die Thrombusbildung wurde als integraler Bestandteil der angeborenen Immunität identifiziert und als Immunthrombose bezeichnet. Es ist bekannt, dass die Aktivierung von Wirtsabwehrsystemen zu einer pro-thrombotischen Umgebung führt. In diesem System interagieren sowohl zelluläre Bestandteile als auch lösliche Faktoren miteinander, die bei einer Dysregulation den pathologischen Prozess der Thromboinflammation induzieren können. Diese Mechanismen wurden während der COVID-19-Pandemie verstärkt untersucht. In dieser Übersichtsarbeit konzentrieren wir uns auf die zugrunde liegenden Mechanismen, die zur Thromboinflammation führen als ein Auslöser der venösen Thromboembolien.

Keywords

thromboinflammation - immunothrombosis - innate immunity - venous thromboembolism - COVID-19

Schlüsselwörter

Thromboinflammation - Immunthrombose - angeborene Immunität - venöse Thromboembolien - COVID-19


Publication History

Received: 30 June 2021

Accepted: 04 October 2021

Article published online:
23 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Raskob GE, Angchaisuksiri P, Blanco AN. et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
    CrossrefPubMedGoogle Scholar
  • 2 Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 2021; 18 (09) 666-682
    CrossrefPubMedGoogle Scholar
  • 3 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13 (01) 34-45
    CrossrefPubMedGoogle Scholar
  • 4 Delabranche X, Helms J, Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care 2017; 7 (01) 117
    CrossrefPubMedGoogle Scholar
  • 5 Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019; 133 (09) 906-918
    CrossrefPubMedGoogle Scholar
  • 6 von Brühl M-L, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
    CrossrefPubMedGoogle Scholar
  • 7 van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 2011; 24 (03) 273-278
    CrossrefPubMedGoogle Scholar
  • 8 Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103 (01) 56-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Obi AT, Andraska E, Kanthi Y. et al. Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia. Thromb Haemost 2017; 117 (02) 339-348
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Hippenstiel S, Suttorp N. Interaction of pathogens with the endothelium. Thromb Haemost 2003; 89 (01) 18-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002; 8 (03) 242-250
    CrossrefPubMedGoogle Scholar
  • 12 Mojiri A, Nakhaii-Nejad M, Phan W-L. et al. Hypoxia results in upregulation and de novo activation of von Willebrand factor expression in lung endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33 (06) 1329-1338
    CrossrefPubMedGoogle Scholar
  • 13 Ponomaryov T, Payne H, Fabritz L, Wagner DD, Brill A. Mast cells granular contents are crucial for deep vein thrombosis in mice. Circ Res 2017; 121 (08) 941-950
    CrossrefPubMedGoogle Scholar
  • 14 Brill A, Fuchs TA, Chauhan AK. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117 (04) 1400-1407
    CrossrefPubMedGoogle Scholar
  • 15 Michels A, Dwyer CN, Mewburn J. et al. von Willebrand factor is a critical mediator of deep vein thrombosis in a mouse model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2020; 40 (12) 2860-2874
    CrossrefPubMedGoogle Scholar
  • 16 Guo L, Rondina MT. The era of thromboinflammation: platelets are dynamic sensors and effector cells during infectious diseases. Front Immunol 2019; 10: 2204
    CrossrefPubMedGoogle Scholar
  • 17 Becattini C, Agnelli G, Schenone A. et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    CrossrefPubMedGoogle Scholar
  • 18 Brighton TA, Eikelboom JW, Mann K. et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
    CrossrefPubMedGoogle Scholar
  • 19 Stewart GJ. Neutrophils and deep venous thrombosis. Haemostasis 1993; 23 (Suppl. 01) 127-140
    PubMedGoogle Scholar
  • 20 Subramaniam S, Jurk K, Hobohm L. et al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 2017; 129 (16) 2291-2302
    CrossrefPubMedGoogle Scholar
  • 21 Hisada Y, Ay C, Auriemma AC, Cooley BC, Mackman N. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost 2017; 15 (11) 2208-2217
    CrossrefPubMedGoogle Scholar
  • 22 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
    CrossrefPubMedGoogle Scholar
  • 23 Elaskalani O, Abdol Razak NB, Metharom P. Neutrophil extracellular traps induce aggregation of washed human platelets independently of extracellular DNA and histones. Cell Commun Signal 2018; 16 (01) 24
    CrossrefPubMedGoogle Scholar
  • 24 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Brill A, Fuchs TA, Savchenko AS. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10 (01) 136-144
    CrossrefPubMedGoogle Scholar
  • 26 Sorvillo N, Cherpokova D, Martinod K, Wagner DD. Extracellular DNA NET-works with dire consequences for health. Circ Res 2019; 125 (04) 470-488
    CrossrefPubMedGoogle Scholar
  • 27 Carestia A, Kaufman T, Schattner M. Platelets: new bricks in the building of neutrophil extracellular traps. Front Immunol 2016; 7: 271
    CrossrefPubMedGoogle Scholar
  • 28 Martinod K, Demers M, Fuchs TA. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A 2013; 110 (21) 8674-8679
    CrossrefPubMedGoogle Scholar
  • 29 Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110 (05) 910-919
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Schmidt CQ, Verschoor A. Complement and coagulation: so close, yet so far. Blood 2017; 130 (24) 2581-2582
    CrossrefPubMedGoogle Scholar
  • 31 Fletcher-Sandersjöö A, Bellander B-M. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res 2020; 194: 36-41
    CrossrefPubMedGoogle Scholar
  • 32 de Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol 2019; 16 (01) 19-27
    CrossrefPubMedGoogle Scholar
  • 33 Foley JH, Walton BL, Aleman MM. et al. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 2016; 5: 175-182
    CrossrefPubMedGoogle Scholar
  • 34 Nørgaard I, Nielsen SF, Nordestgaard BG. Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen General Population Study. Clin Chem 2016; 62 (03) 525-534
    CrossrefPubMedGoogle Scholar
  • 35 Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111 (2, Suppl): S460-S475
    CrossrefPubMedGoogle Scholar
  • 36 Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 2020; 108 (01) 17-41
    CrossrefPubMedGoogle Scholar
  • 37 Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis 2020; 51 (02) 313-329
    CrossrefPubMedGoogle Scholar
  • 38 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
    CrossrefPubMedGoogle Scholar
  • 39 Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021; 76 (04) 412-420
    CrossrefPubMedGoogle Scholar
  • 40 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-1034
    CrossrefPubMedGoogle Scholar
  • 41 Qin C, Zhou L, Hu Z. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71 (15) 762-768
    CrossrefPubMedGoogle Scholar
  • 42 Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020; 194: 101-115
    CrossrefPubMedGoogle Scholar
  • 43 Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109 (22) 2698-2704
    CrossrefPubMedGoogle Scholar
  • 44 Ranucci M, Ballotta A, Di Dedda U. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18 (07) 1747-1751
    CrossrefPubMedGoogle Scholar
  • 45 Magro C, Mulvey JJ, Berlin D. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1-13
    CrossrefPubMedGoogle Scholar
  • 46 Carvelli J, Demaria O, Vély F. et al; Explore COVID-19 IPH group, Explore COVID-19 Marseille Immunopole group. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 2020; 588 (7836): 146-150
    CrossrefPubMedGoogle Scholar
  • 47 Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020; 46 (06) 1105-1108
    CrossrefPubMedGoogle Scholar
  • 48 Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41 (32) 3038-3044
    CrossrefPubMedGoogle Scholar
  • 49 Janiuk K, Jabłońska E, Garley M. Significance of NETs formation in COVID-19. Cells 2021; 10 (01) 151
    CrossrefPubMedGoogle Scholar
  • 50 Middleton EA, He X-Y, Denorme F. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020; 136 (10) 1169-1179
    CrossrefPubMedGoogle Scholar
  • 51 Leppkes M, Knopf J, Naschberger E. et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 2020; 58: 102925
    CrossrefPubMedGoogle Scholar
  • 52 Nicolai L, Leunig A, Brambs S. et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 2020; 142 (12) 1176-1189
    CrossrefPubMedGoogle Scholar
  • 53 Krauel K, Duerschmied D. ICODE: the international COVID-19 thrombosis biomarkers colloquium-novel soluble biomarkers: circulating cell-free nucleic acids and other molecules. J Thromb Thrombolysis 2021 May 12:1–5. doi: 10.1007/s11239-021-02468-6. Epub ahead of print.
    PubMedGoogle Scholar
  • 54 Zuo Y, Zuo M, Yalavarthi S. et al. Neutrophil extracellular traps and thrombosis in COVID-19. J Thromb Thrombolysis 2021; 51 (02) 446-453
    CrossrefPubMedGoogle Scholar
  • 55 Petito E, Falcinelli E, Paliani U. et al; COVIR study investigators. Association of neutrophil activation, more than platelet activation, with thrombotic complications in coronavirus disease 2019. J Infect Dis 2021; 223 (06) 933-944
    CrossrefPubMedGoogle Scholar
  • 56 Skendros P, Mitsios A, Chrysanthopoulou A. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 2020; 130 (11) 6151-6157
    CrossrefPubMedGoogle Scholar
  • 57 Hasan Ali O, Bomze D, Risch L. et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. Clin Infect Dis 2020; ciaa1496: ciaa1496
    PubMedGoogle Scholar
  • 58 Xiao M, Zhang Y, Zhang S. et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol 2020; 72 (12) 1998-2004
    CrossrefPubMedGoogle Scholar
  • 59 Borghi MO, Beltagy A, Garrafa E. et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol 2020; 11: 584241
    CrossrefPubMedGoogle Scholar
  • 60 Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. Reality check on antiphospholipid antibodies in COVID-19-associated coagulopathy. Arthritis Rheumatol 2021; 73 (01) 173-174
    CrossrefPubMedGoogle Scholar
  • 61 Violi F, Cammisotto V, Pignatelli P. Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets 2021 Jun 7:1-9. doi: 10.1080/09537104.2021.1936478. Epub ahead of print.
    PubMedGoogle Scholar
  • 62 Bonaventura A, Vecchié A, Dagna L. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21 (05) 319-329
    CrossrefPubMedGoogle Scholar